AUTHORS
Rupayan Kundu, MD, Rishabh Kundu, MS2, Sudipto Mukherjee, MD, PhD, MPH3
AFFILIATIONS
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Case Western Reserve University, Cleveland, Ohio, United States
3 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
ABSTRACT
Introduction:
Leukemia remains a major cause of cancer-related morbidity and mortality in the United States. This study aimed to evaluate the epidemiological trends (incidence and mortality rates), attributable risk factors, and future projections of Leukemia in the United States (USA).
Methods:
This study analyzed data from 1990 to 2023 retrieved from the Global Health Data Exchange 2023 database, a comprehensive repository of global health and demographic information. Age-standardized incidence rates (ASIR), age-standardized death rates (ASDR), and attributable risk factors for leukemia in the USA were evaluated and expressed per 100,000 person-years: overall, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Chronic Lymphocytic Leukemia (CLL). However, the strength of these associations was not formally validated. Differences in age-standardized rates between 1990 and 2023 were assessed using a two-sample t-test. All statistical analyses were performed in R (version 4.5.3). An autoregressive integrated moving average (ARIMA) model was trained using data through 2023 and subsequently applied to forecast trends through 2050.
Result:
In 2023, there were an estimated 64,892 new cases of leukemia and 30,015 deaths in the United States (USA). The ASIR for leukemia was 11.81 in 2023 compared with 15.51 in 1990 (p=0.2), while the ASDR was 5.09 in 2023 compared with 7.04 in 1990 (p=0.7). From 1990 to 2023, leukemia demonstrated declining trends in both ASIR and ASDR, with an annual percentage change (APC) of - 0.24 for ASIR and - 0.28 for ASDR.
Among leukemia subtypes, from 1990 to 2023, CML showed the greatest decline in both ASIR (APC: - 0.65) and ASDR (APC: - 0.73), whereas AML was the only subtype with an increasing ASIR (APC: 0.13) and a nearly stable ASDR (APC: - 0.01). ALL and CLL demonstrated declining ASIR and ASDR.
Among the states of the USA, in 2023, the highest ASIR for overall leukemia was observed in Minnesota (15.64), while the highest ASDR was observed in West Virginia (6.55). From 1990 to 2023, all USA states experienced declines in leukemia ASIR and ASDR, with the greatest reductions observed in the District of Columbia (APC of ASIR: - 0.36; APC of ASDR: - 0.56).
Risk factor: In this dataset, high BMI (body mass index), smoking, and occupational exposure to carcinogens were identified as risk factors for leukemia. In 2023, smoking was the leading attributable risk factor for leukemia mortality, accounting for 19.49% of deaths, followed by high BMI (12.52%) and occupational carcinogens (0.46%). From 1990 to 2023, mortality attributable to high BMI increased by 26.65% and smoking by 2.68%, whereas mortality attributable to occupational exposure to carcinogens decreased by 10.54%.
Projection: Our analysis projects that the ASIR of leukemia in the USA will continue to decline through 2050 across all leukemia subtypes. The ASDR is also projected to decline for ALL and CML, whereas it is expected to remain relatively stable for AML and CLL.
Conclusion:
Although the burden of leukemia has declined over the past three decades in the United States, important differences persist across leukemia subtypes and geographic regions. Smoking and high BMI remain major contributors to leukemia-related mortality, highlighting opportunities for targeted risk reduction strategies. While leukemia incidence is projected to continue declining through 2050, mortality trends are expected to vary by subtype, underscoring the need for continued surveillance and subtype-specific public health and clinical strategies to reduce the future burden of leukemia.
DISCLOSURES
Rupayan Kundu, MD: No relevant conflicts of interest to declare.